Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II/III: Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Trial of BHV-3500 for the Acute Treatment of Migraine

NCT03872453 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03872453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03872453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II/III: Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Trial of BHV-3500 for the Acute Treatment of Migraine
Lead sponsor
Pfizer
Phase
Phase 2/3
Overall status
Completed
Start date
March 25, 2019
Completion date
November 11, 2019
Enrollment
2,154 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

migraine